A very interesting read, shared by our BEAMER colleagues at Pfizer. It identifies not only risk factors for adherence in three disease areas, but also the potentially most effective interventions to improve adherence. The conclusions of this 2022 publication are fully in line with our rationale in 2017 to start developing our Adherence Risk Management (ARM) services for clinical studies.
Tell us more. Solutions from Link2Trials go one step further. Let us know your goals